medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 1

<< Back Next >>

salud publica mex 2016; 58 (1)

Decrease of HCV seroprevalence in Mexico: Results from the National Health and Nutrition Survey 2012

Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero-Martínez M, Hernández-Ávila M

Language: Spanish
References: 24
Page: 25-32
PDF size: 228.39 Kb.


ABSTRACT

Objective. To estimate seroprevalence of hepatitis C virus (HCV) among 15-49 years old Mexicans living in households and to describe the profile of seroreactive individuals. Materials and methods. Cross-sectional study implemented in 2012 using a national probabilistic sample with behavioral data from face-to-face interviews at households and HCV antibodies screening using capillary blood from same individuals. Results. HCV seroprevalence in Mexico was estimated at 0.27% (IC95% 0.12-0.60), representing 161 000 persons. Seroprevalence was significantly higher among males (0.45% CI95% 0.01-0.89) than females (0.10% CI95% 0.00-0.22). Multivariate analysis suggests a higher possibility of HCV reactivity among men, increasing with age and higher among those sexually active, and lower for higher socioeconomic level. Conclusion. HCV seroprevalence in Mexico by 2012 seems significantly lower than the estimation from 2000 of 1.2% for the same age-group. Evidence of infection among individuals 15-19 years old suggests the need to strength preventive actions, particularly in subjects with risky behaviors.


REFERENCES

  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases 2005;5(9):558-67.

  2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13(17):2436-41.

  3. Lavanchy D. The global burden of hepatitis C. Liver International 2009;29:74-81. doi: 10.1111/j.1478-3231.2008.01934.x.

  4. Averhoff FM, Glass N, Holtzman D. Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States. Clinical Infectious Diseases 2012;55(suppl 1):S10-S5. doi: 10.1093/cid/cis361.

  5. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-1342. doi: 10.1002/hep.26141.

  6. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepúlveda J. Seroprevalencia de la hepatitis C en adultos de México: ¿un problema de salud pública emergente? Salud Pública de Mex 2007;49:s395-s403.

  7. Panduro A, Melendez GE, Fierro NA, Madrigal BR, Zepeda-Carrillo EA, Román S. Epidemiología de las hepatitis virales en México. Salud Publica de Mex 2011;53:S37-S45.

  8. Chiquete E, Panduro A. Low Prevalence of Anti-Hepatitis C Virus Antibodies in Mexico: A Systematic Review. Intervirology 2006;50:1-8.

  9. Panduro A, Roman S, Khan A, Tanaka Y, Kurbanov F, Martinez-Lopez E, et al. Molecular epidemiology of hepatitis C virus genotypes in west Mexico. Virus Res 2010;151:19-25.

  10. Burguete-García AI, Conde-González CJ, Jiménez-Méndez R, Juárez- Díaz Y, Meda-Monzón E, Torres-Poveda K, et al. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Publica de Mex 2011;53:S7-S12.

  11. Consensus Statement EASL International Consensus Conference on Hepatitis C. J Hepatol 1999; 31(Suppl 1):3-8.

  12. Normal Oficial Mexicana NOM-033-SSA2-1993. Recolección y manejo de sangre humana y sus componentes con fines terapéuticos. Diario Oficial de la Federación. 1993.

  13. Vera-de-León L, Juárez-Navarro J, Díaz-Gómez M, Méndez-Navarro J, Chirino-Sprung R, Dheesa-Violante M, et al. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005;70(1):25-32.

  14. Vázquez-Flores J, Valiente-Banuet L, Marín L, Sánchez-Guerrero A. La seguridad de las reservas sanguíneas en la República Mexicana durante los años 1999 a 2003. Rev Inves Clin 2006;58(2):101-8.

  15. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver International 2011;31:18-29. doi: 10.1111/j.1478- 3231.2011.02538.x.

  16. Fundación Mexicana para la Salud Hepática. La hepatitis C como un problema de salud pública en México. Salud Pública Mex 2011;53(1):S61-S7.

  17. Romero-Martínez M, Shamah-Levy T, Franco-Núñez A, Villalpando S, Cuevas-Nasu L, Gutiérrez JP, et al. Encuesta Nacional de Salud y Nutrición 2012: diseño y cobertura. Salud Publica Mex 2012;55(S2):332-40.

  18. Sepúlveda J, Tapia-Conyer R, Velásquez O, Valdespino JL, Olaiz-Fernández G, Kuri P, et al. Diseño y metodología de la Encuesta Nacional de Salud 2000. Salud Pública de Mex 2007;49:s427-s32.

  19. Gutiérrez JP, Conde-González CJ, Walker DM, Bertozzi SM. Herpes simplex virus type 2 among Mexican high school adolescents: prevalence and association with community characteristics. Arch Med Res 2007;38:774-82.

  20. Hogrefe WR, Ernst C, Su X. Efficiency of reconstitution of immunoglobin g from blood specimens dried on filter paper and utility in herpes simplex virus type-specific serology screening. Clin Diagn LabImmunol 2002;9:1338-42.

  21. Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero- Martínez M, Hernández-Avila M. Seroprevalencia de VIH en población mexicana de entre 15 y 49 años: resultados de la Ensanut 2012. Salud Pública Mex 2014;56(4):323-32.

  22. Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology 2013;57(3):881-9. doi: 10.1002/hep.26164.

  23. White EF, Garfein RS, Brouwer KC, Lozada R, Ramos R, Firestone-Cruz M, et al. Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Pública de Mex 2007;49:165-72.

  24. Senado de la República. Dictamen de la Comisión de Salud de una proposición con punto de acuerdo que exhorta a la Secretaría de Salud para que realice detecciones con instrumentos no invasivos e incorpore tratamientos de última generación que han comprobado su eficacia en la erradicación del virus de la hepatitis C. Aprobado el 21 de abril de 2015. [documento en línea] México: Gaceta 127 del Senado de la República, 2015 [consultado el 24 de agosto de 2015]. Disponible en: http://www. senado.gob.mx/index.php?ver=sp&mn=2&sm=2&id=54162




2020     |     www.medigraphic.com